Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
14.34
+0.89 (6.62%)
At close: Aug 24, 2026, 4:00 PM EDT
14.61
+0.27 (1.86%)
Pre-market: Aug 25, 2026, 6:03 AM EDT
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $2.96M in the quarter ending June 30, 2026, a decrease of -89.54%. This brings the company's revenue in the last twelve months to $29.37M, down -75.95% year-over-year. In the year 2025, Arcturus Therapeutics Holdings had annual revenue of $82.03M, down -46.14%.
Revenue (ttm)
$29.37M
Revenue Growth
-75.95%
P/S Ratio
13.88
Revenue / Employee
$264,577
Employees
111
Market Cap
407.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.03M | -70.28M | -46.14% |
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | 20.79M | 5.04M | 31.97% |
| Dec 31, 2018 | 15.75M | 2.76M | 21.20% |
| Dec 31, 2017 | 13.00M | -7.38M | -36.23% |
| Dec 31, 2016 | 20.38M | 14.24M | 232.06% |
| Dec 31, 2015 | 6.14M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 65.26M |
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 59.22M |
| Capricor Therapeutics | 11.13M |
| Upstream Bio | 3.16M |
| Palisade Bio | 500.00K |
| Lyell Immunopharma | 27.00K |
ARCT News
- 13 days ago - Arcturus Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 17 days ago - Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord - TheFly
- 18 days ago - Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Arcturus Therapeutics Holdings Earnings release: Q2 2026 - Filings
- 18 days ago - Arcturus Therapeutics Holdings Quarterly report: Q2 2026 - Filings
- 18 days ago - Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - Business Wire
- 27 days ago - Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 - Business Wire
- 5 weeks ago - Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire